Clinical Trial Update: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, PK/PD, dosing, and efficacy of RLS-0071 for hospitalized patients with steroid-refractory acute graft-versus-host dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• RLS-0071 (RLS-0071)

Snippet

Sponsor: ReAlta Life Sciences, Inc. | Conditions: Steroid Refractory GVHD | Phase 2 | Status: RECRUITING